Scott A McDonald1, Venetia Qendri2,3, Johannes Berkhof3, Hester E de Melker2, Johannes A Bogaards2. 1. Centre for Infectious Disease Control, National Institute for Public Health and the Environment, PO Box 1, 3720 BA, Bilthoven, The Netherlands. scott.mcdonald@rivm.nl. 2. Centre for Infectious Disease Control, National Institute for Public Health and the Environment, PO Box 1, 3720 BA, Bilthoven, The Netherlands. 3. VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Abstract
PURPOSE: Besides cervical cancer, HPV infection is linked to a multitude of diseases in both males and females, suggesting that vaccination programmes should be re-evaluated, with a judicious assessment made of the disease burden stratified by sex, age, and genotype. Projections of burden into the near future are also needed to provide a benchmark for evaluating the impact of vaccination programmes, and to assess the need for scaling-up preventive measures. METHODS: Using the disability-adjusted life-years (DALY) measure, we estimated the total HPV-associated disease burden in the Netherlands. Annual cancer registrations over the period 1989-2014 for all cancers with an aetiological link to HPV infection were retrieved, supplemented by incidence data on high-grade cervical intraepithelial neoplasia (CIN) and anogenital warts. RESULTS: Over the recent period 2011-2014, the average annual HPV disease burden was 10,600 DALYs (95% credible interval (CrI):10,260-10,960) in females and 3,346 DALYs (95% CrI: 2,973-3,762) in males. Burden was dominated by cervical cancer, but its share amongst women decreased from 89% in 1989 to 77% in 2014. The male share of the total disease burden increased from 9.8% in 1989 to 26% in 2014. In 2023 (before the expected clinical impact from vaccinating girls), total burden is forecasted at 1.3-fold larger than in 2014. CONCLUSIONS: The HPV-associated disease burden is higher than that reported for any other infectious disease in the Netherlands, with a larger burden observed in women than in men. The rapidly rising male share of the total burden underlines the prioritization of male HPV-related disease in prevention programmes.
PURPOSE: Besides cervical cancer, HPV infection is linked to a multitude of diseases in both males and females, suggesting that vaccination programmes should be re-evaluated, with a judicious assessment made of the disease burden stratified by sex, age, and genotype. Projections of burden into the near future are also needed to provide a benchmark for evaluating the impact of vaccination programmes, and to assess the need for scaling-up preventive measures. METHODS: Using the disability-adjusted life-years (DALY) measure, we estimated the total HPV-associated disease burden in the Netherlands. Annual cancer registrations over the period 1989-2014 for all cancers with an aetiological link to HPV infection were retrieved, supplemented by incidence data on high-grade cervical intraepithelial neoplasia (CIN) and anogenital warts. RESULTS: Over the recent period 2011-2014, the average annual HPV disease burden was 10,600 DALYs (95% credible interval (CrI):10,260-10,960) in females and 3,346 DALYs (95% CrI: 2,973-3,762) in males. Burden was dominated by cervical cancer, but its share amongst women decreased from 89% in 1989 to 77% in 2014. The male share of the total disease burden increased from 9.8% in 1989 to 26% in 2014. In 2023 (before the expected clinical impact from vaccinating girls), total burden is forecasted at 1.3-fold larger than in 2014. CONCLUSIONS: The HPV-associated disease burden is higher than that reported for any other infectious disease in the Netherlands, with a larger burden observed in women than in men. The rapidly rising male share of the total burden underlines the prioritization of male HPV-related disease in prevention programmes.
Entities:
Keywords:
Anogenital warts; Cancer; Disability-adjusted life-years; Disease burden; Human papillomavirus
Authors: Vita W Jongen; Maarten F Schim van der Loeff; Anders Boyd; Mariska Petrignani; Maria Prins; Marcel van der Wal; Astrid Nielen; Hester de Melker; Theo G W M Paulussen; Catharina J Alberts Journal: Hum Vaccin Immunother Date: 2020-09-23 Impact factor: 3.452
Authors: Alies van Lier; Brechje de Gier; Scott A McDonald; Marie-Josée J Mangen; Maarten van Wijhe; Elisabeth A M Sanders; Mirjam E Kretzschmar; Hans van Vliet; Hester E de Melker Journal: Euro Surveill Date: 2019-05
Authors: Petra J Woestenberg; Johannes A Bogaards; Audrey J King; Suzan Leussink; Marianne Ab van der Sande; Christian Jpa Hoebe; Birgit Hb van Benthem Journal: Int J Cancer Date: 2018-12-21 Impact factor: 7.396
Authors: Marc Arbyn; Elisabete Weiderpass; Laia Bruni; Silvia de Sanjosé; Mona Saraiya; Jacques Ferlay; Freddie Bray Journal: Lancet Glob Health Date: 2019-12-04 Impact factor: 26.763
Authors: Marc Arbyn; Murat Gultekin; Philippe Morice; Pekka Nieminen; Maggie Cruickshank; Philip Poortmans; Daniel Kelly; Mario Poljak; Christine Bergeron; David Ritchie; Dietmar Schmidt; Maria Kyrgiou; Ann Van den Bruel; Laia Bruni; Partha Basu; Freddie Bray; Elisabete Weiderpass Journal: Int J Cancer Date: 2020-08-04 Impact factor: 7.396
Authors: Javier Díez-Domingo; Víctor Sánchez-Alonso; Rafael-J Villanueva; Luis Acedo; José Tuells Journal: Int J Environ Res Public Health Date: 2021-01-22 Impact factor: 3.390